Document:

CONSULTING AGREEMENT

 

THIS CONSULTING AGREEMENT
(this “Agreement”) made as of the 31 day of May __ 2012, by and between Brainstorm Cell Therapeutics Inc.,
a Delaware Corporation, with offices at 605 Third Avenue, New York, NY 10158, USA (“Parent”), Brainstorm Cell
Therapeutics Ltd., a wholly owned subsidiary of Parent, a private company organized under the Laws of the State of Israel, whose
principal office is located at 12 Bazel Street, Petach Tiqva, Israel (the “Company”, and together with Parent,
the “Group”) and Dr. Daniel Offen, Israeli I.D. No _______ residing at Kfar Haroeh 38955, Israel, Osek
Mourshe” No. _______(the “Consultant”).

  

WHEREAS, following an
assignment agreement executed between the Parent and the Company dated December 20, 2011 with effective date of January 1, 2007,
the Company is a party to that Second Amended and Restated License Agreement dated July 26, 2007 by and between the Parent
and Ramot at Tel Aviv University Ltd. (“Ramot”), as amended on December 24, 2009 (together with all
exhibits and schedules, the “License Agreement”) relating to certain stem cell technology developed
by Consultant together with other researchers at the Felsenstein Medical Research Center of Tel-Aviv University (“TAU”).

  

WHEREAS, the Parent
and the Consultant entered into a Consulting Agreement dated July 31, 2004 (the “First Agreement”); and

 

WHEREAS, the parties
wish to terminate the First Agreement and wish to enter into this Consulting Agreement pursuant to which Group shall receive certain
services in a defined field from the Consultant, and the Consultant shall furnish such services to the Group as an independent
contractor, absent of an employment relationship between the parties, on the terms and conditions set forth herein; and

 

WHEREAS,
the Company and the Consultant desire to define the relationship between them in accordance to the terms and conditions of this
Agreement;

 

NOW, THEREFORE, the parties agree as follows:

 

		1.	Scope of Services.

 

		1.1	The Consultant hereby agrees to
                                                                act as a consultant and provide the services to the Group as set
                                                                forth in Exhibit A (the “Services”).
                                                                The terms of this Agreement shall be effective as of January 1,
                                                                2012 (the “Effective Date”).

 

		1.2	The Services to be performed shall be provided solely by the Consultant. The Consultant shall perform
the Services to the best of his skill, ability, expertise, experience and effort in a diligent, trustworthy, businesslike and efficient
manner for the purpose of advancing the Group and performance of the Consultant’s duties hereunder.

 

		2.	Consideration. In consideration
                                                            for the Services hereunder, the Company agrees to pay the Consultant
                                                            the amounts set forth in Exhibit A, plus Value Added Tax, against
                                                            provision of a valid tax receipt (the “Consideration”).
                                                            The Consultant will invoice the Company for the Services provided
                                                            by Consultant in each month. The Consideration shall be paid within
                                                            30 days net of the invoice date (shotef+30), provided that
                                                            an invoice was received.

 

The Consultant declares that he
maintains financial books in accordance with applicable law, and that he is duly registered with the income tax, VAT and national
insurance (Bituach Leumi) authorities.

 

The Consultant shall be responsible
for, and shall indemnify and hold the Company harmless from duly and timely paying any and all taxes in connection with the provision
of the Services hereunder, or any remuneration provided in connection therewith. Without derogating from the foregoing, the Company
shall withhold all taxes and compulsory payments on any payment or benefit to the Consultant as required by applicable law.

 

    	1

    	 

    

 

		3.	Expenses.
                                                                                                     The Company shall reimburse
                                                                                                     the Consultant, for all actual
                                                                                                     expenses reasonably and properly
                                                                                                     incurred by the Consultant
                                                                                                     in fulfilling his obligations
                                                                                                     under this Agreement, including
                                                                                                     travel, lodging and meals,
                                                                                                     provided such expenses were
                                                                                                     approved in advance and in
                                                                                                     writing by the Company. Reimbursement
                                                                                                     shall be made by the Company
                                                                                                     against duly issued invoice
                                                                                                     or receipt.

 

		4.	Confidentiality. Upon execution
                                                            of this Agreement, the Consultant will execute the attached Confidentiality
                                                            and Non-Competition Agreement, attached hereto as Exhibit B,
                                                            which constitutes an integral part of this Agreement.

 

		5.	Representation
                                                                              and Warranties.

 

		5.1	     Each of the Consultant and the Company represents that: (i) he/it is entitled to enter into this
Agreement and to assume all the obligations hereunder, (ii) the execution and delivery of this Agreement and the fulfillment of
the terms hereof (a) will not constitute a default under or conflict with any agreement or other instrument to which he or it is
a party or by which he or it is bound, (b) will not result in a breach of any confidentiality undertaking to any third party and
the Consultant represents that in performing the Services hereunder he shall not use any proprietary information of any third party,
(c) does not require the consent of any person or entity except as provided herein, (d) there are no contracts, impediments, hindrances
or restrictive covenants preventing the full performance of his or its duties and obligations hereunder, and nothing contained
in this Agreement shall require or permit the Consultant or the Company to do any act inconsistent with the requirements of any
statute, regulation or rule under any applicable law.

 

		5.2	     The parties hereto hereby agree to the termination of the First Agreement as of the Effective Date.
As full and final consideration for any amounts due under the First Agreement, the Parent will pay the Consultant $36,000 (Thirty
six thousand dollars), for 2011 services, by issuance of shares of common stock of the company, par value $0.0005, according to
the market price of shares on the issuance date. Following such a payment, the Consultant hereby irrevocably waives any claim and/or
demand against the Group in connection with the First Agreement and its termination.

 

		6.	Relationship
                                                                              of Parties; Indemnity.

 

		6.1	The Company and the Consultant agree that the Consultant is an “independent contractor”
and that except as otherwise stated in this Agreement, the Company shall have no right to control or direct the manner in which
the Consultant performs his duties and services under this Agreement. The Consultant must perform and continue to perform all actions
legally required to establish and maintain his status as an independent contractor. The Consultant understands and agrees that
except as specifically provided in this Agreement, no member of the Group grants the Consultant the right or authority to make
or give any agreement statement, representation, warranty or other commitment, or to create any obligation of any kind, on behalf
of any member of the Group. This Agreement shall not be construed to create any relationship of employment, association, agency,
partnership or joint venture between any member of the Group and the Consultant, nor shall it be construed to create any relationship
other than that of principal and independent contractor between any member of the Group and the Consultant. The Consultant is not
an employee of any member of the Group, and no member of the Group shall be obligated to treat the Consultant as an employee.

 

    	2

    	 

    

  

		6.2	The Consultant shall be responsible, solely and exclusively, to comply with all of his obligations
under the law, including, without limitation, for the payments of all taxes applicable to him as an independent contractor and
with respect to payment of applicable social security, national insurance (Bituach Leumi), health insurance and other legal requirements.
The Consultant will defend, indemnify and hold the Group harmless from and against all claims, damages, losses and expenses, including
reasonable fees and expenses of attorneys and other professionals relating to any obligation imposed upon any member of the Group
to pay any withholding taxes, social security, unemployment or disability insurance or similar items in connection with the Consideration
received by Consultant.

 

		6.3	The Consultant undertakes that neither he nor anyone on his behalf shall bring claims against
                                                                any member of the Group with any cause of action based on employee-employer relations between the Consultant and any member
                                                                of the Group. It is agreed between the parties that, if despite the parties’ express representations and agreements
                                                                hereunder, it shall at any time be held by any competent judicial authority, that the relationship between the Consultant and
                                                                any member of the Group in respect of the Services provided pursuant to this Agreement is one of employer and employee, the
                                                                following provisions shall apply:

 

6.3.1.    Retroactively,
from the Effective Date and in lieu of any Consideration, the Consultant shall be deemed to have been entitled only to a gross
monthly salary (including for all over-time hours, if relevant) in an amount equal to 60% of the Consideration and all the remaining
amounts shall be deemed to have been paid on account of all payments and social benefits (whether required to be paid to an employee
under law, contract, custom or otherwise) and the Consultant shall not be deemed to have been entitled to any other payments or
benefits under law or otherwise. From the date of such holding and thereafter, the Consultant shall only be entitled to the gross
monthly salary in an amount equal to 60% of the Consideration and to the social benefits mandated under the law. All amounts paid
or payable to Consultant will be subject to withholding in accordance with applicable law;

 

6.3.2.    The
Company shall be entitled to set off from the amounts due to the Consultant pursuant to this Agreement and/or in accordance with
any other source the amounts which the Consultant is liable to refund to it pursuant to this Section or in accordance with any
other source.

 

		6.4	in the event that the Company shall be demanded and/or obligated, to pay any amount, give the Consultant
or any third party any right, deriving from the existence of the client-consultant relationship between the Consultant and the
Company, the Consultant shall indemnify the Company, within fourteen (14) days of its first demand, for any and all costs, liabilities
and expenses it may have in connection with such demand and/or obligation, including the economical value of such right and including
legal expenses.

 

		6.5	The terms of this Section 6 shall survive termination
of this Agreement,

 

		6.6	The Group shall indemnify the Consultant and shall hold him harmless from and against any loss,
damage, liability and expense (including attorney fees and legal costs) caused to or incurred by him as a result of third party
claims filed against him and arising out of or resulting from the performance of the Consultant of the Services and/or the use
by the Company of any information developed or provided by the Consultant in the performance of the Services, except for acts which
involve his willful misconduct. The Company shall insure the aforesaid liability.

 

		7.	Term and Termination.

 

		7.1	This Agreement
                                                                                  shall commence on the effective date set forth
                                                                                  in Exhibit A (the “Effective
                                                                                  Date”), and shall continue in force
                                                                                  for a period of one year and, unless previously
                                                                                  terminated, shall automatically renew for one
                                                                                  year periods each thereafter (the “Term”).
                                                                                  Notwithstanding the above, either party shall
                                                                                  be entitled to terminate this Agreement by thirty
                                                                                  (30) days prior written notice.

 

    	3

    	 

    
 

		7.2	Notwithstanding
                                                                                                                                                       anything
                                                                                                                                                       else
                                                                                                                                                       to
                                                                                                                                                       the
                                                                                                                                                       contrary
                                                                                                                                                       herein,
                                                                                                                                                       the
                                                                                                                                                       Company
                                                                                                                                                       may
                                                                                                                                                       terminate
                                                                                                                                                       the
                                                                                                                                                       Consultant’s
                                                                                                                                                       engagement
                                                                                                                                                       at
                                                                                                                                                       any
                                                                                                                                                       time
                                                                                                                                                       by
                                                                                                                                                       written
                                                                                                                                                       notice
                                                                                                                                                       for
                                                                                                                                                       Cause.
                                                                                                                                                       In
                                                                                                                                                       such
                                                                                                                                                       event,
                                                                                                                                                       this
                                                                                                                                                       Agreement
                                                                                                                                                       and
                                                                                                                                                       the
                                                                                                                                                       consulting
                                                                                                                                                       relationship
                                                                                                                                                       shall
                                                                                                                                                       be
                                                                                                                                                       deemed
                                                                                                                                                       effectively
                                                                                                                                                       terminated
                                                                                                                                                       as
                                                                                                                                                       of
                                                                                                                                                       the
                                                                                                                                                       time
                                                                                                                                                       of
                                                                                                                                                       delivery
                                                                                                                                                       of
                                                                                                                                                       such
                                                                                                                                                       notice,
                                                                                                                                                       the
                                                                                                                                                       Consultant
                                                                                                                                                       will
                                                                                                                                                       not
                                                                                                                                                       be
                                                                                                                                                       entitled
                                                                                                                                                       to
                                                                                                                                                       any
                                                                                                                                                       payment
                                                                                                                                                       in
                                                                                                                                                       lieu
                                                                                                                                                       of
                                                                                                                                                       notice
                                                                                                                                                       period
                                                                                                                                                       and
                                                                                                                                                       any
                                                                                                                                                       office
                                                                                                                                                       which
                                                                                                                                                       the
                                                                                                                                                       Consultant
                                                                                                                                                       held
                                                                                                                                                       with
                                                                                                                                                       or
                                                                                                                                                       function
                                                                                                                                                       performed
                                                                                                                                                       for
                                                                                                                                                       the
                                                                                                                                                       Parent
                                                                                                                                                       shall
                                                                                                                                                       terminate
                                                                                                                                                       immediately.
                                                                                                                                                       For
                                                                                                                                                       purposes
                                                                                                                                                       of
                                                                                                                                                       this
                                                                                                                                                       Agreement,
                                                                                                                                                       termination
                                                                                                                                                       for
                                                                                                                                                       “Cause”
                                                                                                                                                       shall
                                                                                                                                                       mean
                                                                                                                                                       and
                                                                                                                                                       include:
                                                                                                                                                       (a)
                                                                                                                                                       conviction
                                                                                                                                                       of
                                                                                                                                                       any
                                                                                                                                                       crime
                                                                                                                                                       involving
                                                                                                                                                       moral
                                                                                                                                                       turpitude;
                                                                                                                                                       (b)
                                                                                                                                                       action
                                                                                                                                                       taken
                                                                                                                                                       by
                                                                                                                                                       the
                                                                                                                                                       Consultant
                                                                                                                                                       to
                                                                                                                                                       intentionally
                                                                                                                                                       harm
                                                                                                                                                       the
                                                                                                                                                       Group;
                                                                                                                                                       (c)
                                                                                                                                                       theft,
                                                                                                                                                       self-dealing
                                                                                                                                                       or
                                                                                                                                                       embezzlement
                                                                                                                                                       of
                                                                                                                                                       funds
                                                                                                                                                       of
                                                                                                                                                       the
                                                                                                                                                       Company;
                                                                                                                                                       (d)
                                                                                                                                                       any
                                                                                                                                                       material
                                                                                                                                                       breach
                                                                                                                                                       of
                                                                                                                                                       confidentiality
                                                                                                                                                       or
                                                                                                                                                       non-compete
                                                                                                                                                       obligations
                                                                                                                                                       or
                                                                                                                                                       of
                                                                                                                                                       the
                                                                                                                                                       fiduciary
                                                                                                                                                       duties
                                                                                                                                                       or
                                                                                                                                                       duties
                                                                                                                                                       of
                                                                                                                                                       care
                                                                                                                                                       to
                                                                                                                                                       the
                                                                                                                                                       Group.

 

		7.3	Upon the termination of the Services hereunder, the Consultant shall promptly deliver to the Company
or Parent all books, memoranda, plans, computer software, customer lists, records and data of every kind in whatever form or medium
relating to the business and affairs of the Group which are then in his possession or control. Upon termination of this Agreement,
for any reason, Consultant shall cooperate with the Group and use his best efforts to assist with the integration into the Group
of the person or persons who will assume Consultant’s responsibilities.

 

		8.	Deliverables and Discoveries

 

All work products resulting
from provision of the Services (the “Deliverables”) shall vest solely with the Company. Notwithstanding the
above, should any work product resulting from the provision of the Services result in the creation or development of intellectual
property which may entitle its owner to patent protection (“Discoveries”) such Discoveries shall be deemed
“Joint Inventions” under the License Agreement and be covered by the terms and conditions of the License Agreement.

 

		9.	Miscellaneous.

 

		9.1	Notice. For the purpose of this Agreement, notices and all other communications
                                                             provided for in the Agreement shall be in writing and shall be deemed to have been duly given on receipt if delivered
                                                             personally, upon receipt of a facsimile confirmation if faxed, two days after being sent by a nationally recognized
                                                             overnight                                                              carrier, three days after being mailed by certified
                                                             mail, postage prepaid, return receipt requested, or twenty four (24)
                                                             hours following the submission of an email message, addressed to the respective addresses set forth below or last given by
                                                             each party to the other, except that notice of change of address shall be effective only upon receipt. The initial
                                                             addresses of the parties for purposes of this Agreement shall be as set forth in Exhibit
                                                             A.

 

All notices, requests, demands,
payments invoices and other communications which are required or may be given under this Agreement shall be in writing and shall
be deemed to have been duly given

 

		9.2	No Waiver. No provision of this Agreement may be modified, waived or discharged unless such
waiver, modification or discharge is agreed to in writing and signed by the Consultant, the Company and the Parent. No waiver by
either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this
Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the
same or at any prior or subsequent time.

 

		9.3	Governing Law. This Agreement
                                                                shall be governed by and construed and enforced in accordance
                                                                with the laws of the State of Israel without giving effect to
                                                                the principles of conflict of law thereof. Any disputes arising
                                                                under or in relation to this Agreement shall be resolved exclusively
                                                                by the competent court in Tel Aviv.

 

    	4

    	 

    
 

 

		9.4	Severability. The provisions of this Agreement shall be deemed severable and the invalidity
or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof, and any provision
deemed unenforceable by a court of competent jurisdiction shall be replaced by an enforceable provision that most nearly approximates
the intent of the unenforceable provision. In the event that a court of competent jurisdiction shall determine that any provision
of this Agreement or the application thereof is unenforceable in whole or in part because of the duration, scope or geographic
area thereof, the parties hereto agree that said court in making such determination shall have the power to reduce the duration,
scope or geographic area of such provision to the extent necessary to make it enforceable, and that the Agreement in its reduced
form shall be valid and enforceable to the full extent permitted by law.

 

		9.5	Entire Agreement. This
                                                                Agreement, including the exhibits, constitutes the entire agreement
                                                                between the parties hereto and supersedes all prior agreements
                                                                understandings and arrangements, oral or written, between the
                                                                parties hereto with respect to the subject matter hereof. No agreement
                                                                or representations, oral or otherwise, express or implied,
                                                                with respect to the subject matter hereof have been made by either
                                                                party which are not expressly set forth in this Agreement.

 

		9.6	Assignment. The Company shall have the right to assign this Agreement to any affiliate or
subsidiary of the Company or any corporation or other entity owning or acquiring all or substantially all the assets and business
of the Company whether by operation of law or otherwise. Neither this Agreement nor any right or interest hereunder shall be assignable
or transferable by the Consultant, its beneficiaries or legal representatives.

 

		9.7	Interpretation. The section headings contained herein are for reference purposes only and
shall not in any way affect the meaning or interpretation of this Agreement. The preamble to this Agreement constitutes an integral
part hereof.

 

IN WITNESS WHEREOF the parties have signed this
Agreement as of the date first hereinabove set forth.

 

	Brainstorm Cell Therapeutics Ltd.	 	Consultant
	Name:	Liat Sossover	 	Name:	Dr. Daniel Offen
	Title:	CFO	 	ID#:	
	Signature:	/s/ Liat Sossover	 	Signature:	/s/ Daniel Offen
	 	 	 	 	 
	Dated:	May 14, 2012	 	Dated:	20 May 2012
	 	 	 	 	 
	Brainstorm Cell Therapeutics Inc.	 	 	 
	Name:	 Adrian Harel	 	 	 
	Title:	A. CEO	 	 	 
	Signature:	/s/ Adrian Harel	 	 	 
	 	 	 	 	 
	Dated:	9/5/2012	 	 	 

 

The undersigned, Ramot at Tel Aviv
University Ltd., confirm and consent to the terms of Section 8 of the above Consulting Agreement.

 

	Name:	Shlomo Nimrodi	 
	Title:	CEO	 
	Signature:	/s/ Shlomo Nimrodi	 
	 	 	 
	Dated:	 	 

 

    	5

    	 

    
 

Exhibit
A

 

	Name of Consultant:	Dr. Daniel Offen
	 	 
	I.D. Number:	
	 	 
	Consultant Address:	Kfar Haroeh 38955, Israel
	 	Email: danioffen@gmail.com
	 	 
	Company Address:	at 12 Bazel Street., Petach Tiqva, Israel
	 	Fax: 03-9236385
	 	Email: lsossover@brainstorm-cell.com
	 	 
	Effective Date:	January 1, 2012
	 	 
	Term:	As defined in the Agreement.
	 	 
	Services:	1.	Scientific consulting
	 	 	-          Assist, if needed, Group in characterization of MSC-NTF cells 
	 	 	-          Advise on new protocols to test the efficacy of the MSC-NTF cells
	 	 	-          Advise in planning of pre-clinical tests/efficacy studies for new applications
	 	 	-          Assist/advice in planning clinical trials that use MSC-NTF cells in new indications
	 	 	-          Provide management with required scientific advice/affairs
	 	2.	Patent filing opinion;
	 	 	-          Advice Group and the Patent law firm in patent phrasing
	 	 	-          Revise or Assist in scientific answers to Patent Office Action
	 	 	-          Assist in
    preparing scientific answers/ replies to the patent examiners
	 	3.	Potential investors:
	 	 	-          Assist preparing scientific slides to be included in presentations to investors
	 	 	-          Accompany management to meetings with potential investors to describe on Group’s inventions
	 	4.	Scientific conferences:
	 	 	-          Assist in preparing of scientific summaries, posters and Abstracts 
	 	 	-          Represent Group in/at scientific conferences
	 	5.	Scientific publications: assist the Group in phrasing scientific publications and articles
	 	6.	Present Scientific Seminars– give scientific lectures on scientific topics, that are out of the scope of Group
    activities and research.

 

    	6

    	 

    
 

	Time Devotion:	The Consultant agrees to devote approximately one day a week for the provision of the Services  
     
	 	 
	Consideration:	$3,000 per month, plus VAT, commencing as of the Effective Date, subject to receipt of applicable invoice. In addition,
    Consultant shall be entitled to $3,000 per month to be paid by way of issuance of shares of the Parent. Such issuance shall
    be made twice a year. The number of Parent shares to be issued shall be based on the Parent share market closing price on
    the date of issuance.  

 

    	7

    	 

    
 

Exhibit
B

 

CONFIDENTIALITY AND NON-COMPETITION

AGREEMENT

 

My obligations under this
Confidentiality and Non-Competition Agreement are towards Brainstorm Cell Therapeutics, Inc. and Brainstorm Cell Therapeutics
Ltd. (collectively, “Company”), and towards their present and future parent companies, subsidiaries, affiliates
and successors. All of the aforementioned entities shall be referred to collectively as the “Company’s
Entities”.

 

1.     Confidentiality

 

I will
regard and retain as confidential and will not divulge to any third party, or use for any unauthorized purposes either during or
after the term of my provision of services to the Company, any confidential information, which is proprietary of the Company or
other third parties, that I have acquired during my Services or in connection with my Services or contacts with the Company’s Entities,
without the written consent of an authorized representative of the Company. This obligation of confidence and non-use shall not
apply to:

		(a)	Information disclosed to me by the Company which, at the time of disclosure, is published or known publicly or is otherwise
in the public domain;

		(b)	Information which, after it is disclosed by the Company is published or becomes part of the public domain through no fault
of mine;

		(c)	Information disclosed to me which was known by me before the time of disclosure as evidenced by written records;

		(d)	Information which has been or hereafter is disclosed to me in good faith by a third party who was not under any obligation
of confidence or secrecy to the Company at the time of disclosure to me; and

		(e)	Information that has been independently developed at TAU or elsewhere without reference to the Confidential Information disclosed
to me as aforesaid.

 

Nothing herein shall be deemed
to limit, in any way, Ramot’s, TAU’s or my publication rights pursuant to Section 9.2 of the License Agreement with respect to
the Discoveries.

 

2.     Confidential Information

 

Confidential Information shall include,
but will not be limited to, information regarding research and development related to actual or anticipated products, inventions,
whether patentable or non-patentable, hardware, software or other products, methods of manufacture, trade secrets, business plans,
customer lists, finances, and any other data related to the business or affairs of the Company or the Company’s Entities. Confidential
information will include information in written, oral or any other form of communication.

 

3.     Return of Confidential Information

 

All materials including, but not limited
to, documents, notes, memoranda, records, diagrams, blueprints, bulletins, formulas, reports, computer programs, and any other
material of any kind and in any form, coming into my possession or prepared by me in connection with my service, are the exclusive
property of the Company (“Documents”). I agree to return to the Company all such Documents upon termination of my engagement
by the Company, unless I acquire the Company’s specific written consent to release any such Document.

 

    	8

    	 

    
 

4.    Non
Competition

 

During the term of my engagement and for
a period of 18 months following such termination, I agree that I will not, either alone or jointly with others, or as an agent,
consultant or employee of any person, firm or company, directly or indirectly, carry on or engage in any activity or business
in the field of mesenchymal stem cells for neurodegenerative diseases (the “Field of Business”). For
the avoidance of doubt I shall not accept any work offered to me by Ramot in the Field of Business during the above non compete
period.

 

The above limitation shall not apply to
the development of medicine or cell treatment from other sources, such as muscle cells or cells from the mouth, for treatment of
nuerological or psychiatric diseases.

 

5.    Non-Solicitation

 

During the term of my provision of Services
to the Company and thereafter for a period of 12 months, I will not solicit or encourage or cause others to solicit or encourage
any employees of the Company’s Entities to terminate their employment with the Company, and I will not assist any employees of
the Company’s Entities to engage with any Competing Entities.

 

6.    Non
Conflicting Obligations

 

I will not disclose to the Company any
proprietary or confidential information belonging to any third party, including any prior or current employer or contractor, unless
I have first received the written approval of that third party. 1 am allowed to be engaged by other commercial third parties for
any purpose, provided that (i) such third party’s activities and products will not compete or conflict, directly
with the Company’s activities and products solely in the field of mesenchymal stem cells secreting neurotrophic factors for the
treatment of neurodegenerative diseases. (ii) my engagement with such third parties will not conflict with my duties and undertakings
hereunder, and (iii) in my engagement by such third parties I will not infringe any of the terms and conditions of this Agreement,
including, without limitation, with respect to confidentiality, non-compete, and intellectual property rights.

 

7.    Third
Party Information

 

I
recognize that the Company has received and will in the future receive from third parties their confidential or proprietary
information, subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for
certain limited purposes. I agree to hold all such confidential or proprietary information in the strictest confidence and not
to disclose it to any person or entity or to use it except as necessary in carrying out my position with the Company, consistent
with the Company’s agreement with such third party.

 

8.    Breach of Obligation

 

I am aware that a breach of any of the
obligations under this Agreement will cause the Company or the Company’s Entities serious and irreparable harm, to which no monetary
compensation can be an appropriate remedy. Therefore. 1 agree that if such a breach occurs, the Company shall be entitled, without
prejudice, to take all legal means necessary, including any injunctive relief, to restrain any continuation or further breach of
this Agreement.

 

9.    Assignment

 

This Agreement may be assigned by the Company.
I may not assign or delegate my obligations under this Agreement without the Company’s prior written approval.

 

    	9

    	 

    
 

10.  Survival

 

My obligations under this Agreement
shall remain in full  force for a period of 5 years from termination, for any reason, of my engagement with the Company,
except for confidentiality which shall not be limited in time.

 

11.  Severability

 

The provisions of this Agreement shall
be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of
the other provisions hereof, and any provision deemed unenforceable by a court of competent jurisdiction shall be replaced by an
enforceable provision that most nearly approximates the intent of the unenforceable provision. In the event that a court of competent
jurisdiction shall determine that any provision of this Agreement or the application thereof is unenforceable in whole or in part
because of the duration, scope or geographic area thereof, the parties hereto agree that said court in making such determination
shall have the power to reduce the duration, scope or geographic area of such provision to the extent necessary to make it enforceable,
and that the Agreement in its reduced form shall be valid and enforceable to the full extent permitted by law.

 

12.  Condition to Engagement

 

I acknowledge that execution of this Agreement
is a condition to the Company’s engagement with me and the disclosure of any Confidential Information. I hereby declare and acknowledge
that my confidentiality and non-competition obligations under this Agreement are fair, reasonable, and proportional and are designed
to protect the Company’s and the Company’s Entities’ secrets and their confidential information, which constitute the essence of
their protected business and commercial advantage in which significant capital investments were made.

 

IN
WITNESS WHEREOF, I hereunto set my hand:

 

	/s/ D. Offen	 	20 May 2012
	Dr. Daniel Offen	 	Date

 

    	10eXHIBIT
10.57

 

SECURITIES
PURCHASE AGREEMENT

 

This Securities Purchase
Agreement (this “Agreement”) is dated as of _______ ___, 2012, between Brainstorm Cell Therapeutics Inc., a
Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

 

WHEREAS, subject to
the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act
of 1933, as amended (the “Securities Act”), the Company desires to issue and sell to each Purchaser, and each
Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in
this Agreement.

 

NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

 

ARTICLE I.

DEFINITIONS

 

1.1         Definitions.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:

 

“Acquiring
Person” shall have the meaning ascribed to such term in Section 4.5.

 

“Action”
shall have the meaning ascribed to such term in Section 3.1(j).

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Board
of Directors” means the board of directors of the Company.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.

 

“Closing”
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.

 

“Closing
Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii)
the Company’s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than
the third Trading Day following the date hereof.

 

    	1

    	 

    

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $0.00005 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.

 

“Company
Counsel” means BRL Law Group LLC, with offices located at 425 Boylston Street, 3rd Floor, Boston, Massachusetts 02116.

 

“Disclosure
Schedules” means the Disclosure Schedules of the Company delivered concurrently herewith.

 

“EGS”
means Ellenoff Grossman & Schole LLP, with offices located at 150 East 42nd Street, New York, New York 10017.

 

“Escrow
Agent” means __________, with offices located at ________________.

 

“Escrow
Agreement” means the escrow agreement entered into prior to the date hereof, by and among the Company, the Escrow Agent
and Maxim Group LLC pursuant to which the Purchasers shall deposit Subscription Amounts with the Escrow Agent to be applied to
the transactions contemplated hereunder.

 

“Evaluation
Date” shall have the meaning ascribed to such term in Section 3.1(r).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Exempt
Issuance” means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company
pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors
or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities upon the exercise
or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the date of this Agreement or securities issuable pursuant to agreements
to which the Company is a party as of the date hereof (such as the April 13, 2010 Agreement by and among the Company, Dr. Abraham
Israeli and Hadasit Medical Research Services and Development Ltd., as amended), provided that such securities and such agreements
to issue securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities, (c) up to 300,000 shares of Common Stock to be issued
to Company Counsel as payment for general corporate legal work that was provided to Company during 2012, and (d) securities issued
pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided
that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the
Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.

 

    	2

    	 

    

 

“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.

 

“FDA”
shall have the meaning ascribed to such term in Section 3.1(gg).

 

“FDCA”
shall have the meaning ascribed to such term in Section 3.1(gg).

 

“GAAP”
shall have the meaning ascribed to such term in Section 3.1(h).

 

“Indebtedness”
shall have the meaning ascribed to such term in Section 3.1(z).

 

“Intellectual
Property Rights” shall have the meaning ascribed to such term in Section 3.1(o).

 

“Liens”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

“Material
Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).

 

“Material
Permits” shall have the meaning ascribed to such term in Section 3.1(m).

 

“Per
Share Purchase Price” equals $[_____], subject to adjustment for reverse and forward stock splits, stock dividends, stock
combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Pharmaceutical
Product” shall have the meaning ascribed to such term in Section 3.1(gg).

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

 

    	3

    	 

    

 

“Prospectus”
means the final prospectus filed for the Registration Statement.

 

“Prospectus
Supplement” means the supplement to the Prospectus complying with Rule 430A of the Securities Act that is filed with
the Commission and delivered by the Company to each Purchaser at the Closing.

 

“Purchaser
Party” shall have the meaning ascribed to such term in Section 4.8.

 

“Registration
Statement” means the effective registration statement with Commission file No. 333-179331 which registers the sale of
the Shares, the Warrants and the Warrant Shares to the Purchasers.

 

“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(e).

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“Rule
430A” means Rule 430A promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“SEC
Reports” shall have the meaning ascribed to such term in Section 3.1(h).

 

“Securities”
means the Shares, the Warrants and the Warrant Shares.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Shares”
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.

 

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but
shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock). 

 

“Subscription
Amount” means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription Amount,”
in United States dollars and in immediately available funds.

 

    	4

    	 

    

 

“Subsidiary”
means any subsidiary of the Company as set forth on Schedule 3.1(a), and shall, where applicable, also include any direct
or indirect subsidiary of the Company formed or acquired after the date hereof.

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT (formerly NYSE AMEX), the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global
Select Market, the New York Stock Exchange or the OTC Bulletin Board (or any successors to any of the foregoing).

 

“Transaction
Documents” means this Agreement, the Warrants and any other documents or agreements executed in connection with the transactions
contemplated hereunder.

 

“Transfer
Agent” means American Stock Transfer & Trust Company LLC, the current transfer agent of the Company, with a mailing
address of 6201 15th Avenue, Brooklyn, New York 11219 and a facsimile number of (718) 765-8717, and any successor transfer agent
of the Company.

 

“Variable
Rate Transaction” shall have the meaning ascribed to such term in Section 4.12(b).

 

“Warrants”
means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a)
hereof, which Warrants shall be exercisable immediately and have a term of exercise equal to [___] years, in the form of Exhibit
A attached hereto.

 

“Warrant
Shares” means the shares of Common Stock issuable upon exercise of the Warrants.

 

ARTICLE II.

PURCHASE AND SALE

 

2.1         Closing.
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution
and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, up to an aggregate of $[________] of Shares and Warrants. Each Purchaser shall deliver to the Escrow Agent,
via wire transfer or a certified check, immediately available funds equal to such Purchaser’s Subscription Amount as set
forth on the signature page hereto executed by such Purchaser and the Company shall deliver to each Purchaser its respective Shares
and a Warrant as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth
in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3,
the Closing shall occur at the offices of EGS or such other location as the parties shall mutually agree. 

 

    	5

    	 

    

 

2.2         Deliveries.

 

(a)          On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:

 

(i)          this
Agreement duly executed by the Company;

 

(ii)         a
legal opinion of Company Counsel, substantially in the form of Exhibit B attached hereto;

 

(iii)        a
copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via
The Depository Trust Company Deposit or Withdrawal at Custodian system (“DWAC”) Shares equal to such Purchaser’s
Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;

 

(iv)        a
Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to [___]% of such Purchaser’s
Shares, with an exercise price equal to $[_____], subject to adjustment therein (such Warrant may be delivered within three Trading
Days of the Closing Date); and

 

(v)         the
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).

 

(b)          On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company or the Escrow Agent, as applicable,
the following:

 

(i)          this
Agreement duly executed by such Purchaser; and

 

(ii)         to
the Escrow Agent, such Purchaser’s Subscription Amount by wire transfer to the account specified in the Escrow Agreement.

 

2.3         Closing
Conditions. 

 

(a)          The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

 

(i)          the
accuracy in all material respects on the Closing Date of the representations and warranties of the Purchasers contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);

 

(ii)         all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and

 

(iii)        the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.

 

    	6

    	 

    

 

(b)          The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:

 

(i)          the
accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Company contained
herein (unless as of a specific date therein);

 

(ii)         all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;

 

(iii)        the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;

 

(iv)        there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and

 

(v)         from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company’s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg
L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are
reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States
or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national
or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in
each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the
Closing.

 

ARTICLE III.

REPRESENTATIONS AND WARRANTIES

 

3.1         Representations
and Warranties of the Company. Except as set forth in the Disclosure Schedules, which
Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent
of the disclosure contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations
and warranties to each Purchaser:

 

(a)          Subsidiaries.
All of the direct and indirect subsidiaries of the Company are set forth on Schedule 3.1(a).
The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear
of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully
paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. 

 

    	7

    	 

    

 

(b)          Organization
and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity
or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects
or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect
on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document
(any of (i), (ii) or (iii), a “Material Adverse Effect”) and no Proceeding has been instituted in any such jurisdiction
revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

 

(c)          Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by
it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company
and no further action is required by the Company, the Board of Directors or the Company’s stockholders in connection herewith
or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which
it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the
terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance
with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.

 

    	8

    	 

    

 

(d)          No
Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any
of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which
any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)
and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

 

(e)          Filings,
Consents and Approvals. Except for those that have already been obtained, the Company is not required to obtain any consent,
waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state,
local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company
of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with
the Commission of the Prospectus Supplement, (iii) application(s) to each applicable Trading Market for the listing of the Shares
and Warrant Shares for trading thereon in the time and manner required thereby and (iv) such filings as are required to be made
under applicable state securities laws (collectively, the “Required Approvals”).

 

(f)          Issuance
of the Securities; Registration. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the
Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable,
free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum
number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration
Statement in conformity with the requirements of the Securities Act, which became effective on [_______ __], 2012 (the “Effective
Date”), including the Prospectus, and such amendments and supplements thereto as may have been required to the date of
this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the
effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission
and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission.
The Company, if required by the rules and regulations of the Commission, proposes to file the Prospectus, with the Commission pursuant
to Rule 424(b) or Rule 430A. At the time the Registration Statement and any amendments thereto became effective, at the date of
this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all
material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading;
and the Prospectus and any amendments or supplements thereto, at time the Prospectus or any amendment or supplement thereto was
issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and
did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in light of the circumstances under which they were made, not misleading.

 

    	9

    	 

    

 

(g)          Capitalization.
The capitalization of the Company is as set forth on Schedule 3.1(g). The Company has not issued any capital stock since
its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise
of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock to employees pursuant
to the Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents
outstanding as of the date of the most recently filed periodic report under the Exchange Act. Except as set forth on Schedule
3.1(g), no Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate
in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities or
as set forth on Schedule 3.1(g), there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for,
or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common
Stock Equivalents. The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other
securities to any Person (other than the Purchasers) and will not result in a right of any holder of Company securities to adjust
the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares of capital stock
of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal
and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights
to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others
is required for the issuance and sale of the Securities. Except as set forth on Schedule 3.1(g), there are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company
is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.

 

    	10

    	 

    

 

(h)          SEC
Reports; Financial Statements. Except as set forth on Schedule 3.1(h) attached hereto, the Company has filed all reports, schedules,
forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including
pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company
was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents
incorporated by reference therein, together with the Prospectus and the Prospectus Supplement, being collectively referred to herein
as the “SEC Reports”). As of their respective dates, the SEC Reports complied in all material respects with
the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules
and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been
prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods
involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and
except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit
adjustments.

 

(i)          Material
Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included
within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there has
been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect,
(ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses
incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the
Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not
altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property
to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v)
the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock
option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except
for the issuance of the Securities contemplated by this Agreement or as set forth on Schedule 3.1(i), no event, liability,
fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to
the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made
or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.

 

(j)          Litigation.
Except for Actions (as defined herein) disclosed in the Prospectus, there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any
of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges
the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an
unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary,
nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under
federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company,
there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director
or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.

 

    	11

    	 

    

 

(k)          Labor
Relations. No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’
employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or
any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of
its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance
with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and
conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.

 

(l)          Compliance.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the
Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is
bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any
court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation
of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental
protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as
could not have or reasonably be expected to result in a Material Adverse Effect.

 

(m)          Regulatory
Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material
Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation
or modification of any Material Permit.

 

    	12

    	 

    

 

(n)          Title
to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not
materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens
for the payment of federal, state or other taxes, for which appropriate reserves have been made in accordance with GAAP and, the
payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company
and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries
are in compliance.

 

(o)          Intellectual
Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports
and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”).
None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual
Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2)
years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited
financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual
Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have
a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is
no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken
reasonable security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights, except
where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

(p)          Insurance.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the
Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without
a significant increase in cost.

 

    	13

    	 

    

 

(q)          Transactions
With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of the Company or
any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party
to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or
personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director,
or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case
in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses
incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan
of the Company.

 

(r)          Sarbanes-Oxley;
Internal Accounting Controls. The Company and the Subsidiaries are in compliance with any and all applicable requirements of
the Sarbanes-Oxley Act of 2002 that are effective and applicable to the Company as of the date hereof, and any and all applicable
rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date.
Except as set forth in the SEC Reports, the Company and the Subsidiaries maintain a system of internal
accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s
general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in
conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Except as set forth in the SEC Reports, the Company
and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to
be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported,
within the time periods specified in the Commission’s rules and forms. The Company’s certifying officers have evaluated
the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered
by the most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company
presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the
effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation
Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act)
of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control
over financial reporting of the Company and its Subsidiaries.

 

    	14

    	 

    

 

(s)          Certain
Fees. Except as set forth in the Prospectus Supplement, no brokerage or finder’s fees or commissions are or will be payable
by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank
or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in
this Section that may be due in connection with the transactions contemplated by the Transaction Documents.

 

(t)          Investment
Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will
not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as
amended. The Company shall conduct its business in a manner so that it will not become an “investment company” subject
to registration under the Investment Company Act of 1940, as amended.

 

(u)          Registration
Rights. Except for Persons which have waived such rights in writing, no Person has any right to cause the Company or any Subsidiary
to effect the registration under the Securities Act of any securities of the Company or any Subsidiary on the Registration Statement.

 

(v)          Listing
and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on
which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or
maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable
future continue to be, in compliance with all such listing and maintenance requirements.

 

(w)          Application
of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and
the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation
as a result of the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities.

 

    	15

    	 

    

 

(x)          Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed
in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the
Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they
were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement
taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under which they were made and when
made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties
with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.

 

(y)          No
Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions
of any Trading Market on which any of the securities of the Company are listed or designated.

 

(z)          Solvency.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company’s assets exceeds
the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small capital to carry
on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate
all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in
respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability
to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).
The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation
under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. Schedule 3.1(z) sets
forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the
Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness” means (x) any
liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary
course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether
or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;
and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance
with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.

 

    	16

    	 

    

 

(aa)         Tax
Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject,
(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of
all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid
taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or
of any Subsidiary know of no basis for any such claim.

 

(bb)         Foreign
Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent
or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns
from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person
acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any
provision of FCPA.

 

(cc)         Accountants.
The Company’s accounting firm is set forth on Schedule 3.1(cc) of the Disclosure Schedules. To the knowledge and belief
of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall
express its opinion with respect to the financial statements to be included in the Company’s Annual Report for the fiscal
year ending December 31, 2012.

 

(dd)         Acknowledgment
Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting
solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in
any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given
by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further represents to
each Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based
solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 

    	17

    	 

    

 

(ee)         Acknowledgement
Regarding Purchaser’s Trading Activity. Anything in this Agreement or
elsewhere herein to the contrary notwithstanding (except for Sections 3.2(e) and 4.14 hereof), it is understood and acknowledged
by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist
from purchasing or selling, long and/or short, securities of the Company, or “derivative” securities based on securities
issued by the Company or to hold the Securities for any specified term; (ii) past or future open market or other transactions by
any Purchaser, specifically including, without limitation, Short Sales or “derivative” transactions, before or after
the closing of this or future private placement transactions, may negatively impact the market price of the Company’s publicly-traded
securities; (iii) any Purchaser, and counter-parties in “derivative” transactions to which any such Purchaser is a
party, directly or indirectly, presently may have a “short” position in the Common Stock, and (iv) each Purchaser shall
not be deemed to have any affiliation with or control over any arm’s length counter-party in any “derivative”
transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities
at various times during the period that the Securities are outstanding, including, without limitation, during the periods that
the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if
any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the hedging
activities are being conducted.  The Company acknowledges that such aforementioned hedging activities do not constitute a
breach of any of the Transaction Documents.

 

(ff)         Regulation
M Compliance.  The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases
of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any
other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company’s placement
agent in connection with the placement of the Securities.

 

    	18

    	 

    

 

(gg)         FDA.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical
Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the
failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge,
threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint,
or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received
any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket
clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing
of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall,
suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any
Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries,
(iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent
decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws,
rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have
a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material
respects in accordance with all applicable laws, rules and regulations of the FDA.  The Company has not been informed by the
FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed,
produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product
being developed or proposed to be developed by the Company. 

 

(hh)        Office
of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (“OFAC”).

 

(ii)         U.S.
Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation within the
meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser’s
request.

 

(jj)         Bank
Holding Company Act. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act
of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the
“Federal Reserve”). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly
or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or
more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

 

    	19

    	 

    

 

(kk)         Money
Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money
Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body
or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge
of the Company or any Subsidiary, threatened.

 

3.2         Representations
and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser,
hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific
date therein):

 

(a)          Organization;
Authority. Such Purchaser is either an individual or an entity duly incorporated or
formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right,
corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions
contemplated by this Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery
of this Agreement and performance by such Purchaser of the transactions contemplated by this Agreement have been duly authorized
by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser.
Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser
in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against
it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.

 

(b)          Understandings
or Arrangements. Such Purchaser is acquiring the Securities as principal for its own
account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution
of such Securities (this representation and warranty not limiting such Purchaser’s right to sell the Securities pursuant
to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is
acquiring the Securities hereunder in the ordinary course of its business.

 

(c)          Purchaser
Status. At the time such Purchaser was offered the Securities, it was, and as of the
date hereof it is, and on each date on which it exercises any Warrants, it will be either: (i) an “accredited investor”
as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a “qualified institutional
buyer” as defined in Rule 144A(a) under the Securities Act. Such Purchaser is not required to be registered as a broker-dealer
under Section 15 of the Exchange Act. 

 

    	20

    	 

    

 

(d)          Experience
of Such Purchaser. Such Purchaser, either alone or together with its representatives,
has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits
and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser
is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss
of such investment.

 

(e)          Certain
Transactions and Confidentiality. Other than consummating the transactions contemplated
hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser,
directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the
period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other
Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately
prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle
whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no
direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets,
the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that
made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement,
such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including
the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall
constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or
securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.

 

The Company acknowledges
and agrees that the representations contained in Section 3.2 shall not modify, amend or affect such Purchaser’s right to
rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties contained
in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transaction contemplated hereby.

 

ARTICLE IV.

OTHER AGREEMENTS OF THE PARTIES

 

4.1         Warrant
Shares. If all or any portion of a Warrant is exercised at a time when there is an
effective registration statement to cover the issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless
exercise, the Warrant Shares issued pursuant to any such exercise shall be issued free of all legends. If at any time following
the date hereof the Registration Statement (or any subsequent registration statement registering the sale or resale of the Warrant
Shares) is not effective or is not otherwise available for the sale or resale of the Warrant Shares, the Company shall immediately
notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter shall promptly
notify such holders when the registration statement is effective again and available for the sale or resale of the Warrant Shares
(it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell,
any of the Warrant Shares in compliance with applicable federal and state securities laws). The Company shall use best efforts
to keep a registration statement (including the Registration Statement) registering the issuance or resale of the Warrant Shares
effective during the term of the Warrants. 

 

    	21

    	 

    

 

4.2         Furnishing
of Information. Until the earliest of the time that (i) no Purchaser owns Securities
or (ii) the Warrants have expired, the Company covenants to timely file (or obtain extensions in respect thereof and file within
the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act
even if the Company is not then subject to the reporting requirements of the Exchange Act. 

 

4.3         Integration.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules
and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction. 

 

4.4         Securities
Laws Disclosure; Publicity. The Company shall (a) by 9:00 a.m. (New York City time)
on the Trading Day immediately following the date hereof, issue a press release disclosing the material terms of the transactions
contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the
Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents
to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers
by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with
the transactions contemplated by the Transaction Documents. The Company and each Purchaser shall consult with each other in issuing
any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall
issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect
to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the
Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case
the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing
with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a)
as required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b)
to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers
with prior notice of such disclosure permitted under this clause (b).

 

    	22

    	 

    

 

4.5         Shareholder
Rights Plan. No claim will be made or enforced by the Company or, with the consent
of the Company, any other Person, that any Purchaser is an “Acquiring Person” under any control share acquisition,
business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement
in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan
or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company
and the Purchasers.

 

4.6         Non-Public
Information. Except with respect to the material terms and conditions of the transactions
contemplated by the Transaction Documents, the Company covenants and agrees that neither it, nor any other Person acting on its
behalf will provide any Purchaser or its agents or counsel with any information that the Company believes constitutes material
non-public information, unless prior thereto such Purchaser shall have entered into a written agreement with the Company regarding
the confidentiality and use of such information. The Company understands and confirms that each Purchaser shall be relying on the
foregoing covenant in effecting transactions in securities of the Company.

 

4.7         Use
of Proceeds. Except as set forth on Schedule 4.7
attached hereto, the Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes
and shall not use such proceeds: (a) for the satisfaction of any portion of the Company’s debt (other than payment of trade
payables in the ordinary course of the Company’s business and prior practices), (b) for the redemption of any Common Stock
or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.

 

4.8         Indemnification
of Purchasers. Subject to the provisions of this Section 4.8, the Company will indemnify
and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each
Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act),
and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each,
a “Purchaser Party”) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs
and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of
or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them
or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect
to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such Purchaser
Party’s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such
Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws
or any conduct by such Purchaser Party which constitutes fraud, gross negligence, willful misconduct or malfeasance). If any action
shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser
Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel
of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel
in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of
such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing,
(ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action
there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and
the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no
more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement
by a Purchaser Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed;
or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s
breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in
the other Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount
thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements
contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others
and any liabilities the Company may be subject to pursuant to law.

 

    	23

    	 

    

 

4.9         Reservation
of Common Stock. As of the date hereof, the Company has reserved and the Company shall
continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for
the purpose of enabling the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the
Warrants. 

 

4.10        Listing
of Common Stock. The Company hereby agrees to use best efforts to maintain the listing
or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the
Company shall apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing
of all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the
Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares,
and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other
Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and
trading of its Common Stock on a Trading Market and will comply in all respects with the Company’s reporting, filing and
other obligations under the bylaws or rules of the Trading Market. 

 

4.11        [RESERVED]

 

4.12        Subsequent
Equity Sales. 

 

(a)          From
the date hereof until [____] days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any agreement
to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.

 

    	24

    	 

    

 

(b)          From
the date hereof until the ____ year anniversary of the Closing Date, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents
(or a combination of units thereof) involving a Variable Rate Transaction. “Variable Rate Transaction” means
a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or
exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price
or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common
Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange
price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the
occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the
Common Stock or (ii) enters into any agreement, including, but not limited to, an equity line of credit, whereby the Company may
issue securities at a future determined price. Any Purchaser shall be entitled to obtain injunctive relief against the Company
to preclude any such issuance, which remedy shall be in addition to any right to collect damages.

 

(c)          Notwithstanding
the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall
be an Exempt Issuance.

 

4.13        Equal
Treatment of Purchasers. No consideration (including any modification of any Transaction
Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any of this
Agreement unless the same consideration is also offered to all of the parties to this Agreement. For clarification purposes, this
provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and
is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in
concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.

 

4.14        Certain
Transactions and Confidentiality. Each Purchaser, severally and not jointly with the
other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will
execute any purchases or sales, including Short Sales of any of the Company’s securities during the period commencing with
the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly
announced pursuant to the initial press release as described in Section 4.4.  Each
Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated
by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such
Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the
Disclosure Schedules.  Notwithstanding the foregoing and notwithstanding anything contained
in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation,
warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that
the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company
in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are
first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any
duty of confidentiality to the Company or its Subsidiaries after the issuance of the initial press release as described in Section
4.4.  Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby
separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct
knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets,
the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made
the investment decision to purchase the Securities covered by this Agreement.

 

    	25

    	 

    

 

ARTICLE V.

MISCELLANEOUS

 

5.1         Termination. 
This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing
has not been consummated on or before [_________ ___], 2012; provided, however,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).

 

5.2         Fees
and Expenses. Except as expressly set forth in the Transaction Documents to the contrary,
each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses
incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company
shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction
letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied
in connection with the delivery of any Securities to the Purchasers.

 

5.3         Entire
Agreement. The Transaction Documents, together with the exhibits and schedules thereto,
the Prospectus and the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter
hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which
the parties acknowledge have been merged into such documents, exhibits and schedules.

 

5.4         Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City
time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via
facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is
required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

 

    	26

    	 

    

 

5.5         Amendments;
Waivers. No provision of this Agreement may be waived, modified, supplemented or amended
except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding at least a majority
in interest of the Shares based on the initial Subscription Amounts hereunder or, in the case of a waiver, by the party against
whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement
of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of
any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder
in any manner impair the exercise of any such right.

 

5.6         Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

5.7         Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the
parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder
without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under
this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in
writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the
“Purchasers.”

 

5.8         No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties
hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced
by, any other Person, except as otherwise set forth in Section 4.8.

 

5.9         Governing
Law. All questions concerning the construction, validity, enforcement and interpretation
of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State
of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning
the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents
(whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees
or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for
the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein
(including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not
to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy
thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of the Transaction Documents, then,
in addition to the obligations of the Company under Section 4.8, the prevailing party in such action, suit or proceeding shall
be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.

 

    	27

    	 

    

 

5.10        Survival.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

 

5.11        Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.

 

5.12        Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.

 

5.13        Rescission
and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without
limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election,
demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods
therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to
the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; provided,
however, that, in the case of a rescission of an exercise of a Warrant,
the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise notice concurrently
with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such
Purchaser’s right to acquire such shares pursuant to such Purchaser’s Warrant (including, issuance of a replacement
warrant certificate evidencing such restored right).

 

    	28

    	 

    

 

5.14        Replacement
of Securities. If any certificate or instrument evidencing any Securities is mutilated,
lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation
thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt
of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument
under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance
of such replacement Securities.

 

5.15        Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate.

 

5.16        Payment
Set Aside. To the extent that the Company makes a payment or payments to any Purchaser
pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or
the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential,
set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee,
receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law
or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to
be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or
setoff had not occurred.

 

5.17        Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser
under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be
responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document.
Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto,
shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or
create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the
transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its
rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it
shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser
has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons
of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
EGS. EGS does not represent any of the Purchasers and only represents Maxim Group LLC. The Company has elected to provide all Purchasers
with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to
do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each
other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively
and not between and among the Purchasers.

 

    	29

    	 

    

 

5.18        Liquidated
Damages. The Company’s obligations to pay any partial liquidated damages or
other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all
unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant
to which such partial liquidated damages or other amounts are due and payable shall have been canceled.

 

5.19        Saturdays,
Sundays, Holidays, etc.    If the
last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business
Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.

 

5.20        Construction.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after
the date of this Agreement.

 

5.21        WAIVER
OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT
BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE
LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 

 

(Signature Pages Follow)

 

    	30

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

	Brainstorm
    cell therapeutics inc.	Address for Notice:
	 	12 Bazel St., POB 10019,
	 	Kiryat Aryeh, Petach Tikva,
	 	Israel 49001

	By:	 	 	Fax: (972) -3-923-6385
	 	Name:	 	 
	 	Title:	 	 
	With a copy to (which shall not constitute notice):	 	 

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE FOR PURCHASER FOLLOWS]

 

    	31

    	 

    

 

PURCHASER SIGNATURE PAGES TO BCLI
SECURITIES PURCHASE AGREEMENT

 

IN WITNESS WHEREOF,
the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.

 

Name of Purchaser: ________________________________________________________

 

Signature of Authorized Signatory of
Purchaser: _________________________________

 

Name of Authorized Signatory: _______________________________________________

 

Title of Authorized Signatory: ________________________________________________

 

Email Address of Authorized Signatory:_________________________________________

 

Facsimile Number of Authorized Signatory: __________________________________________

 

Address for Notice to Purchaser:

 

Address for Delivery of Securities to Purchaser (if not same
as address for notice):

 

Subscription Amount: $_________________

 

Shares: _________________

 

Warrant Shares: __________________

 

EIN Number: _______________________

 

 ̈
Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed
to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations
of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded,
(ii) the Closing shall occur on the third (3rd) Trading Day following the date of this Agreement and (iii) any condition
to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company
or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be
a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such
agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.

 

[SIGNATURE PAGES CONTINUE]

 

    	32

    	 

    
  

DISCLOSURE
SCHEDULES

TO THE

SECURITIES PURCHASE AGREEMENT

BY AND AMONG

Brainstorm Cell Therapeutics Inc.

 

and

 

the
purchasers named therein

 

Dated
as of June __, 2012 (the “Agreement”)

 

    	1

    	 

    

 

These disclosure schedules are a series of schedules (the “Disclosure
Schedules”) corresponding to the sections contained in the Securities Purchase Agreement dated as of June __, 2012 (the
“Agreement”), by and among Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”),
and the purchasers identified on the signature pages thereto (the “Buyer”). Capitalized terms used in these
Disclosure Schedules and not otherwise defined herein shall have the respective meanings assigned to them in the Agreement. These
Disclosure Schedules contain the information required to be disclosed pursuant to, and certain exceptions to, the representations
and warranties in the corresponding sections of the Agreement. The section headings and subject headings in the Disclosure Schedules
are for convenience of reference only and shall not be deemed to alter or affect any disclosure in these Disclosure Schedules or
any provision of the Agreement. Matters set forth in the Disclosure Schedules are not necessarily limited to matters required by
the Agreement to be reflected in the Disclosure Schedules. Nothing in the Agreement or in the Disclosure Schedules constitutes
an admission that any information disclosed, set forth or incorporated by reference in the Disclosure Schedules or in the Agreement
is material, constitutes a Material Adverse Effect or is otherwise required by the terms of the Agreement to be so disclosed, set
forth or incorporated by reference. Information disclosed (including the terms of any agreements referenced herein) by the Company
in any one Section of the Disclosure Schedules will also be deemed a disclosure as to all other applicable Sections of the Disclosure
Schedules and the Agreement where such disclosure is readily apparent from the face of such disclosure.

 

The annexes, attachments, and exhibits to these Disclosure Schedules,
if any, form an integral part of these Disclosure Schedules and are incorporated by reference for all purposes as if set forth
fully herein.

 

    	2

    	 

    

  

Schedule 3.1(a)

 

Subsidiaries

 

Brainstorm Cell Therapeutics Ltd.

 

    	3

    	 

    

 

Schedule 3.1(g)

 

Capitalization*

 

Capitalization Overview:

 

Authorized shares: 800,000,000 shares of common stock,
$0.00005 par value.

 

Issued and outstanding: 128,586,644 (as of June 15, 2012).

 

Option pool: As of June 6, 2012, there were 3,225,013
shares available for issuance under the Plans. On May 6, 2012, the Board approved another amendment and restatement of the Plans
to increase the number of shares available for issuance under the Plans by an additional 9,000,000 shares, subject to the approval
of the Company’s stockholders. Our stockholders approved the amendment and restatement of the Plans on June 12, 2012.

 

Options issued: As of June 28, 2012, there were 3,936,665
options outstanding under Company plans.

 

Warrants: 47,582,162 shares of common stock issuable
upon exercise of outstanding warrants as of June 28, 2012, with exercise prices ranging from $0.00005 per share to $1.00 per share.

 

Convertible notes: None.

 

Agreements to issue stock:

 

In addition to the Options and Warrants described above:

 

		·	On April 13, 2010, the Company, Dr. Israeli and Hadasit Medical Research Services and Development Ltd. (“Hadasit”)
entered into an Agreement, which was amended to clarify certain terms on December 31, 2011 (together, the “Hadasit Agreement”)
pursuant to which the Company agreed to grant, for every year of service: (i) options to Dr. Israeli annually during the term of
the Agreement for the purchase of 166,666 shares of our common stock at an exercise price equal to $0.00005 per share and (ii)
warrants to Hadasit annually during the term of the Agreement for the purchase of 33,334 shares of our common stock at an exercise
price equal to $0.00005 per share. Such options and warrants will vest and become exercisable in twelve (12) consecutive equal
monthly amounts.

 

		·	Thomas B. Rosedale, the Managing Member of BRL Law Group LLC, beneficially owned 180,000 shares of our common stock and may
receive additional shares as part of compensation for certain legal services performed by BRL Law Group LLC in 2012. The Company
is in discussion with BRL Law Group LLC regarding the issuance of up to 300,000 shares of Common Stock in exchange for certain
2012 general corporate legal work provided to the Company (which shares are expected to be issued in or about June 2012).

 

    	4

    	 

    

 

		·	Under the Company’s Director Compensation Plan for non-employee directors (the “Director Compensation Plan”)
each eligible director is granted an annual award immediately following each annual meeting of shareholders beginning with the
2011 annual meeting. For non-U.S. directors, this annual award consists of a nonqualified stock option to purchase 100,000 shares
of common stock. For U.S. directors, at their option, this annual award is either (i) a nonqualified stock option to purchase 100,000
shares of common stock or (ii) 100,000 shares of restricted stock. Additionally, each member of the GNC Committee or Audit Committee
receives (i) a nonqualified stock option to purchase 30,000 shares of common stock or (ii) in the case of U.S. directors and at
their option, 30,000 shares of restricted stock. A chairperson of the GNC Committee or Audit Committee will instead of the above
committee award receive (i) a nonqualified stock option to purchase 50,000 shares of common stock or (ii) in the case of U.S. directors
and at their option, 50,000 shares of restricted stock. Any eligible participant who is serving as chairperson of the Board of
Directors of the Company shall also receive (i) a nonqualified stock option to purchase 100,000 shares of common stock or (ii)
in the case of U.S. directors and at their option, 100,000 shares of restricted stock.

 

Right of First Refusal, etc.:

 

ACCBT Corp. (“ACCBT”) has certain rights and privileges
as set forth in the July 2, 2007 Subscription Agreement by and between the Company and ACCBT, as amended, and other related agreements
including a Registration Rights Agreement and Security Holders Agreement, which include but are not limited to the following:

 

For so long as ACCBT or its affiliates hold at least 5% of our
issued and outstanding share capital:

 

		(i)	Board Appointment Right: ACCBT has the right to appoint 50.1% (any fractions to be rounded up to the nearest whole number)
of the members of the Company’s Board of Directors and any of its committees and the Board of Directors of the Subsidiary.

 

		(ii)	Preemptive Right: ACCBT has the right to receive thirty day notice of, and to purchase a pro rata portion (or greater under
certain circumstances where offered shares are not purchased by other subscribers) of, securities issued by the Company, including
options and rights to purchase shares. This preemptive right does not include issuances under the Company’s equity incentive
plans.

 

		(iii)	Consent Right: ACCBT’s written consent is required for certain Company corporate actions, including issuance of shares
(other than existing warrants and issuances under our incentive plans), amendment of our charter or bylaws, repurchase of shares,
declaration or payment of dividends or distributions, related party transactions, non-ordinary course transactions involving $25,000
or more, liquidation or dissolution, the creation, acquisition or disposition of a subsidiary or entry into a joint venture or
strategic alliance, a material change to our business, merger, change of control, sale of the company, any acquisition, and any
payment of cash compensation over $60,000 per year.

 

    	5

    	 

    

 

In addition ACCBT is entitled to demand and piggyback registration
rights, whereby ACCBT may request, upon ten days written notice, that the Company file, or include within a registration statement
to be filed, with the Securities and Exchange Commission for ACCBT’s resale of the ACCBT Subscription Shares, as adjusted,
and the shares of the Company’s common stock issuable upon exercise of the ACCBT Warrants.

 

* All of the above Capitalization numbers are pre-Closing and
do not reflect actions contemplated by the Transaction Documents.

 

    	6

    	 

    

 

Schedule 3.1(h)

 

SEC Reports

 

None.

 

    	7

    	 

    

 

Schedule 3.1(i)

 

Material Changes; Undisclosed Events,
Liabilities or Developments

 

Pursuant to the Hadasit Agreement, on April 13, 2012, the Company
issued to Dr. Israeli 166,666 shares of common stock at an exercise price equal to $0.00005 per share and issued warrants to Hadasit
for the purchase of 33,334 shares of common stock at an exercise price equal to $0.00005 per share.

 

    	8

    	 

    

 

Schedule 3.1(o)

 

Intellectual Property

 

None.

 

    	9

    	 

    

 

Schedule 3.1(z)

 

Solvency - Indebtedness

 

All outstanding secured and unsecured Indebtedness of the
Company:

 

The Company has received from the Israeli Office of the Chief
Scientist (“OCS”) approximately $1.7 million in grants. The Company is obligated to pay royalties to the OCS, amounting
to 3% to 5% of revenues derived from sales of the products funded with the OCS grant, up to an amount equal to 100% of the grant
received.

 

All outstanding secured and unsecured Indebtedness of the
Subsidiary:

 

1) Agreement with Kiriat Hamada for Petach Tikva office rent
– $9,500 per month through March 31, 2013

2) Albar – leasing of cars - $90,000 (approximately $3,500
per month)

3) Hadasit – rental of GMP in Jerusalem – approximately
$67,000 per month. Note: this agreement for the use of 2 clean rooms can be terminated with 30 days prior notice. It is anticipated
that the Company will continue using this space for at least 6 more months.

 

    	10

    	 

    

 

Schedule 3.1(cc)

 

Accountants

 

Brightman Almagor Zohar & Co.

Certified Public Accountants

A Member Firm of Deloitte Touche Tohmatsu.

 

    	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]